Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$50.03 USD
-0.26 (-0.52%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $50.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 301 - 320 ( 338 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
ASBMR Weekend News Included Positive Data From KRN23 in TIO and Positive Subgroup Abaloparatide-SC ACTIVE Trial Result
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
KRN23 Checks All Boxes at ASBMR Including Growth Velocity; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of September 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Multiple Clinical Catalysts in 2H16 as Ultragenyx Reports 2Q16; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Positive rhGUS Data Should Be Sufficient for Approval; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Positive rhGUS Data Should Be Sufficient for Approval; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Breakthrough Therapy Designation for KRN23 Supports the Ultragenyx Approach; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 6
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Unearthing Gems in the Promised Land: An Overview of the Israeli Life Sciences Sector
Provider: H.C. Wainwright & Co., Inc.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Multiple Data Catalysts in 2H16 as Ultragenyx Reports 1Q16; Reiterate OUTPERFORM and Adjusting our PT to $92
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Tumor-Induced Osteomalacia (TIO) Data Support KRN23 Activity; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Case Studies Supportive of rhGUS Efficacy; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Refining Timelines as Ultragenyx Prepares for Pivotal Studies; Reiterate OUTPERFORM and Adjusting our PT to $99
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q4 EPS Loss Higher Than Expected; Maintain Buy Rating and $104 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Multiple Stock-Driving Events On Tap This Year; We Are Initiating Coverage with a Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Expert Call Helps put Dietary Therapy for GLUT1 DS and Potential Role for Triheptanoin into Context
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 11th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D